EX-99.3 5 dp06530e_ex9903.htm
 
EXHIBIT 99.03
 
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United KingdomTel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
 
     
  Press Release  

3 August 2007

Shire plc (the "Company")

Notification of the Exercise of an Option and Sale of Shares by a Director.

The Company was notified by Mr Angus Russell, Chief Financial Officer, on 2 August 2007, of the exercise in London on the same day, of an option over 95,285 ordinary 5p shares in the capital of the Company at an exercise price of £5.26.  Mr Russell chose to use a net settled cashless exercise facility run by the Company which resulted in a total of 54,930 shares being allotted to him.  The option over the remaining 40,355 shares lapsed.

The Company was further notified by Mr Russell on 2 August 2007, of the sale in London on the same day of 54,930 ordinary 5p shares in the capital of the Company at a price of £12.42.

Following this transaction Mr Russell retains share options and stock appreciation rights over a total of 1,077,203 ordinary shares in the Company.


T May
Company Secretary
 
For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252
Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases.  The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
 
Registered in England 2883758  Registered Office as above



Shire’s focused strategy is to develop and market products for specialty physicians.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.


Registered in England 2883758  Registered Office as above